SCHEDULE: BlackRock Discloses Stake in Dianthus Therapeutics
Beneficial Ownership Filing
BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 6.4% of Dianthus Therapeutics Inc.'s common stock as of June 30, 2026.
Summary
- BlackRock, Inc. has filed an amended Schedule 13G, indicating its beneficial ownership of Dianthus Therapeutics Inc. common stock.
- As of June 30, 2026, BlackRock beneficially owns 3,504,166 shares, representing 6.4% of the class of securities.
- This filing is an amendment to a previous filing.
- BlackRock's reporting business units hold sole voting power for 3,433,718 shares and sole dispositive power for 3,504,166 shares.
- No single person's interest in the common stock of Dianthus Therapeutics Inc. exceeds five percent of the total outstanding common shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by an institutional investor and does not contain operational or financial performance updates.
Positives
- BlackRock, a significant institutional investor, has disclosed a substantial stake in Dianthus Therapeutics Inc.
- The filing indicates that BlackRock's ownership is not for the purpose of changing or influencing control of the issuer.
Future Outlook
This filing is primarily a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Dianthus Therapeutics Inc.'s future performance.
Industry Context
StockSavvy.ai notes that institutional investor filings like this Schedule 13G are common for publicly traded companies and indicate significant investment positions. BlackRock's disclosure of a 6.4% stake suggests a notable level of confidence or strategic interest in Dianthus Therapeutics Inc.'s business or market potential.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a major institutional investor like BlackRock may be viewed positively by the market, potentially influencing investor sentiment and share price.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution of the Power of Attorney by BlackRock, Inc. |
| 04/30/2023 | Date of previous Power of Attorney revoked by the new one. |
| 06/30/2026 | Date of event requiring filing of this statement (reporting period end). |
| 07/28/2026 | Date of certification and signature by Spencer Fleming, Managing Director of BlackRock, Inc. |
Keywords
Dianthus Therapeutics, BlackRock, Schedule 13G, Institutional Investor, Beneficial Ownership, Common Stock, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.